| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |



From the Department of Physiology,* University of Melbourne, Parkville, Victoria; the Department of Medicine,
Saint Vincents Hospital, Fitzroy; and the Department of Medicine,
Austin and Repatriation Medical Centre, West Heidelberg, Australia
Neovascularization in the retina and iris of diabetic patients is a major cause of severe visual loss. However, study of these lesions is compromised by the lack of a comparable diabetic rodent model. Because the vasoactive and angiogenic agent, angiotensin II, is involved in diabetic microvascular disease, we aimed to determine whether endothelial cell proliferation could be induced in the retinae and irides of hypertensive transgenic (mRen-2)27 rats that display an enhanced extra-renal renin-angiotensin system (RAS), including the eye. Six-week-old Ren-2, spontaneously hypertensive, and Sprague-Dawley rats received either streptozotocin or control vehicle and were studied for 36 weeks. Additional nondiabetic and diabetic Ren-2 rats were treated throughout with the angiotensin-converting enzyme inhibitor lisinopril (LIS) (10 mg/kg/day in drinking water). Endothelial cell proliferation was only observed in retinae and irides of diabetic Ren-2 rats and was reduced with LIS. In diabetic Ren-2, vascular endothelial growth factor (VEGF) and VEGFR-2 mRNA were increased in retinae and irides and reduced with LIS. Diabetes activated ocular renin in Ren-2 but not Sprague-Dawley rats. The diabetic Ren-2 rat is a model of intraocular endothelial cell proliferation that can be attenuated by RAS blockade via VEGF-dependent pathways. RAS blockade is a potential treatment for vision-threatening diabetic microvascular complications.
This article has been cited by other articles:
![]() |
J. L. Wilkinson-Berka Prorenin and the (Pro)renin Receptor in Ocular Pathology Am. J. Pathol., December 1, 2008; 173(6): 1591 - 1594. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Cohen, E. Hud, V.-Y. Wu, and C. W. Shearman Amelioration of Diabetes-Associated Abnormalities in the Vitreous Fluid by an Inhibitor of Albumin Glycation Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 5089 - 5093. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. de Resende, S. L. Amaral, C. Moreno, and A. S. Greene Congenic strains reveal the effect of the renin gene on skeletal muscle angiogenesis induced by electrical stimulation Physiol Genomics, October 8, 2008; 33(1): 33 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Kelly, Y. Zhang, K. Connelly, A. J. Cox, J. Martin, H. Krum, and R. E. Gilbert Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2860 - H2869. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Phipps, J. L. Wilkinson-Berka, and E. L. Fletcher Retinal Dysfunction in Diabetic Ren-2 Rats Is Ameliorated by Treatment with Valsartan but Not Atenolol Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 927 - 934. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Campbell, C. I. Johnston, D. J. Kelly, E. R. Lumbers, J. Menard, J. W. Ryan, and J. L. Wilkinson-Berka Sandford Lloyd Skinner (1933-2005) Hypertension, September 1, 2005; 46(3): 452 - 453. [Full Text] [PDF] |
||||
![]() |
P. B. Bergman, C. J. Moravski, S. R. Edmondson, V. C. Russo, L. A. Bach, J. L. Wilkinson-Berka, and G. A. Werther Expression of the IGF System in Normal and Diabetic Transgenic (mRen-2)27 Rat Eye Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2708 - 2715. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Yokota, F Mori, K Kai, T Nagaoka, N Izumi, A Takahashi, T Hikichi, A Yoshida, F Suzuki, and Y Ishida Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay Br. J. Ophthalmol., July 1, 2005; 89(7): 871 - 873. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J Kelly, Y. Zhang, R. M Gow, S. Itescu, and R. E Gilbert Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes Diabetes and Vascular Disease Research, May 1, 2005; 2(2): 76 - 80. [Abstract] [PDF] |
||||
![]() |
S. Sarlos and J. L. Wilkinson-Berka The Renin-Angiotensin System and the Developing Retinal Vasculature Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 1069 - 1077. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Feliers, S. Duraisamy, J. L. Barnes, G. Ghosh-Choudhury, and B. S. Kasinath Translational regulation of vascular endothelial growth factor expression in renal epithelial cells by angiotensin II Am J Physiol Renal Physiol, March 1, 2005; 288(3): F521 - F529. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Martin, D. J. Kelly, S. A. Mifsud, Y. Zhang, A. J. Cox, F. See, H. Krum, J. Wilkinson-Berka, and R. E. Gilbert Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-{beta} Cardiovasc Res, February 15, 2005; 65(3): 694 - 701. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. G. Ebrahimian, R. Tamarat, M. Clergue, M. Duriez, B. I. Levy, and J.-S. Silvestre Dual Effect of Angiotensin-Converting Enzyme Inhibition on Angiogenesis in Type 1 Diabetic Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 65 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ohashi, H. Takagi, H. Oh, K. Suzuma, I. Suzuma, N. Miyamoto, A. Uemura, D. Watanabe, T. Murakami, T. Sugaya, et al. Phosphatidylinositol 3-Kinase/Akt Regulates Angiotensin II-Induced Inhibition of Apoptosis in Microvascular Endothelial Cells by Governing Survivin Expression and Suppression of Caspase-3 Activity Circ. Res., April 2, 2004; 94(6): 785 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Wilkinson-Berka, S. Babic, T. de Gooyer, A. W. Stitt, K. Jaworski, L. G. T. Ong, D. J. Kelly, and R. E. Gilbert Inhibition of Platelet-Derived Growth Factor Promotes Pericyte Loss and Angiogenesis in Ischemic Retinopathy Am. J. Pathol., April 1, 2004; 164(4): 1263 - 1273. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |